Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.
A trial looking at treatment for high risk chronic lymphocytic leukaemia (CLL 210)
This trial was for people with chronic lymphocytic leukaemia (CLL) who had a high risk of their leukaemia coming back.
Cancer Research UK supported this trial.
More about this trial
- alemtuzumab (MabCampath) - a type of drug called a monoclonal antibody
- dexamethasone - a steroid
- lenalidomide (Revlimid) - a drug that affects how the immune system works
- how well CamDexRev worked as induction and maintenance therapy for high risk CLL
- more about the side effects
- how these treatments affected quality of life
Summary of results
- 6 months of induction therapy
- stem cell or bone marrow transplant for those who were suitable
- randomisation into maintenance treatment for people whose induction treatment had gone well, but were not suitable for a transplant
- alemtuzumab (MabCampath)
- lenalidomide (Revlimid)
- was well controlled in 8 people (partial remission)
- was very well controlled in 2 people (complete remission)
- 3 people had lenalidomide capsules every day
- 2 people had no further treatment
- 1 person’s leukaemia was still under control (in remission) after 2 years
- 1 person stopped lenalidomide after 2 months because their leukaemia started to grow again (relapse)
- 1 person stopped lenalidomide after 3 months to have a transplant
- a drop in blood cells causing an increased risk of infection such as chest infection
- a drop in blood cells causing an increased risk of tiredness and breathlessness (
- a drop in blood cells causing an increased risk of bleeding problems
- build up of fluid in the legs (oedema)
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Prof A Pettitt
Cancer Research UK
Cancer Research UK Liverpool Cancer Trials Unit (LCTU)
Chugai Pharmaceutical Co Ltd
NIHR Clinical Research Network: Cancer
Royal Liverpool and Broadgreen University Hospital NHS Trust
University of Liverpool
This is Cancer Research UK trial number CRUKE/09/035.